FDA Grants Priority Review to Belzutifan as Pheo/Para Treatment
February 25, 2025
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for
$39.8M
Million in NET research funding
50
Active Research
Projects
17
Countries with ongoing studies
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for
In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a
The Neuroendocrine Tumor Research Foundation (NETRF) has announced our newest neuroendocrine cancer research grant recipients.
You can support a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.
Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.
NETRF hosts free patient and caregiver neuroendocrine tumor conferences to educate and empower individuals to be part of their care planning and live their best life.